Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics and Histone Deacetylase Inhibitors

21 Oct 2016

Abstract excerpt

The histone deacetylase inhibitor valproic acid (VPA) has been used for many decades in neurology and psychiatry. The more recent introduction of the histone deacetylase inhibitors (HDIs) belinostat, romidepsin and vorinostat for treatment of hematological malignancies indicates the increasing popularity of these agents. Belinostat, romidepsin and vorinostat are metabolized or transported by polymorphic enzymes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to HIV/AIDS drug development and treatment
Share to Pharmacological Effects and Toxicity Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27767376
DOI: 10.2217/pgs-2016-0113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics and Histone Deacetylase InhibitorsPMID 27767376Read ↗

Could valproic acid be an effective anticancer agent? The evidence so farSemantic proximity Read ↗

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.Semantic proximity Read ↗

Pharmacogenomics in neurology: current state and future steps.Semantic proximity Read ↗

The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients.Semantic proximity Read ↗

PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.Semantic proximity Read ↗

UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.Semantic proximity Read ↗

The pharmacogenomics of valproic acid.Semantic proximity Read ↗

Diversity of oncopharmacogenetic profile within Spanish population.Semantic proximity Read ↗

UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.Semantic proximity Read ↗

A pharmacogenetic study of vorinostat glucuronidation.Semantic proximity Read ↗

Phenotype versus genotype to optimize cancer dosing in the clinical setting-focus on 5-fluorouracil and tyrosine kinase inhibitors.Semantic proximity Read ↗

Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and TransportersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.